Nasdaq · CIK 0001746473
PLRX PLIANT THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $1.02 on Oct 9, 2026, +3% from the 52-week low and -45% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
PLRXOct 9, 2026 · close 1.02
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at PLIANT THERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | Lily Cheung Chief Human Resource Officer sell | $42k 3,740 shares | -13% | - | |
| 44Moderate | Bernard Coulie President and CEO sell | $587k 52,419 shares | -11% | - | |
| 30Weak | Keith Lamont Cummings Chief Financial Officer sell | $226k 20,148 shares | -7% | - | |
| 22Weak | Hans Hull Chief Business Officer sell | $179k 15,936 shares | -7% | - |
Transactions
The last 22 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | David Raben Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +575,000 | $0.00 | $0 | 575,000 | 10 d ago |
| Jun 5, 2025 | Suzanne Louise Bruhn director | AGrant or award Common Stock (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 9, 2025 |
| Jun 5, 2025 | Gayle A Crowell director | AGrant or award Common Stock (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 9, 2025 |
| Jun 5, 2025 | Darren S Cline director | AGrant or award Common Stock (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 9, 2025 |
| Jun 5, 2025 | John T Curnutte director | AGrant or award Common Stock (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 9, 2025 |
| Jun 5, 2025 | Hoyoung Huh director | AGrant or award Common Stock (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 9, 2025 |
| Jun 5, 2025 | Katharine Knobil director | AGrant or award Common Stock (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 9, 2025 |
| Jun 5, 2025 | Steve E. Krognes director | AGrant or award Common Stock (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 9, 2025 |
| Jun 5, 2025 | Thomas A MCCOURT director | AGrant or award Common Stock (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 9, 2025 |
| Jun 5, 2025 | David E I Pyott director | AGrant or award Common Stock (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 9, 2025 |
| Jan 23, 2025 | Lily Cheung Chief Human Resource Officer | AGrant or award Common Stock | +25,875 | $0.00 | $0 | 50,425 | Jan 27, 2025 |
| Jan 23, 2025 | Bernard Coulie President and CEO | AGrant or award Common Stock | +162,500 | $0.00 | $0 | 593,017 | Jan 27, 2025 |
| Jan 23, 2025 | Hans Hull Chief Business Officer | AGrant or award Common Stock | +40,150 | $0.00 | $0 | 251,708 | Jan 27, 2025 |
| Jan 23, 2025 | Keith Lamont Cummings Chief Financial Officer | AGrant or award Common Stock | +56,650 | $0.00 | $0 | 319,258 | Jan 27, 2025 |
| Jan 23, 2025 | Lily Cheung Chief Human Resource Officer | AGrant or award Stock Option (Right to Buy)derivative | +51,750 | $0.00 | $0 | 51,750 | Jan 27, 2025 |
| Jan 23, 2025 | Keith Lamont Cummings Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +113,300 | $0.00 | $0 | 113,300 | Jan 27, 2025 |
| Jan 23, 2025 | Bernard Coulie President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +325,000 | $0.00 | $0 | 325,000 | Jan 27, 2025 |
| Jan 23, 2025 | Hans Hull Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +80,300 | $0.00 | $0 | 80,300 | Jan 27, 2025 |
| Jan 17, 2025 | Lily Cheung Chief Human Resource Officer | SOpen-market sale Common Stock10b5-1 | -3,740 | $11.20 | $42k | 24,550 | Jan 22, 2025 |
| Jan 17, 2025 | Bernard Coulie President and CEO | SOpen-market sale Common Stock10b5-1 | -52,419 | $11.20 | $587k | 430,517 | Jan 22, 2025 |
| Jan 17, 2025 | Keith Lamont Cummings Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -20,148 | $11.20 | $226k | 262,608 | Jan 22, 2025 |
| Jan 17, 2025 | Hans Hull Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -15,936 | $11.20 | $179k | 211,558 | Jan 22, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Suzanne Louise Bruhndirector
- Gayle A Crowelldirector
- Lily CheungChief Human Resource Officer
- Darren S Clinedirector, officer
- Bernard CouliePresident and CEO
- Keith Lamont CummingsChief Financial Officer
- John T Curnuttedirector
- Hoyoung Huhdirector, owner
- Hans HullChief Business Officer
- Katharine Knobildirector
- Steve E. Krognesdirector
- Thomas A MCCOURTceo, officer, director
- David E I Pyottdirector
- David RabenChief Medical Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.